Gilead Announces Dismissal of Securities Litigation

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 16, 2006--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that on May 12, 2006, Judge Martin J. Jenkins of the United States District Court for the Northern District of California dismissed with prejudice the securities class action complaint filed in 2003 against Gilead and certain of its current and former officers, In re Gilead Sciences Securities Litigation, Case No. C03-4999 MJJ. The complaint had alleged that the defendants violated federal securities laws by making allegedly false and misleading statements in 2003. The plaintiffs have not indicated whether they will appeal the dismissal.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.